1 / 1

Olaparib(Lynparza)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

ASTRAZENECA AB

Formulation:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Lynparza(Olaparib) Instructions:Uses,Dosage, Side Effects

Lynparza is a targeted therapy that inhibits poly (ADP-ribose) polymerase enzymes, disrupting DNA repair in cancer cells. It is approved for use in ovarian, breast, pancreatic, and prostate cancers with identified BRCA or HRR gene mutations. The drug is available in 100 mg and 150 mg tablets and requires biomarker testing for patient selection.

Generic name

Olaparib(Lynparza)

English name

Olaparib

Alternative Names

Lynparza

Drug prices

Indications

Maintenance treatment of BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer after response to first-line platinum-based chemotherapy.

Combination use with bevacizumab for maintenance in HRD-positive advanced ovarian cancer.

Maintenance treatment of recurrent BRCA-mutated ovarian cancer after platinum-based therapy.

Adjuvant treatment of germline BRCA-mutated, HER2-negative, high-risk early breast cancer after neoadjuvant or adjuvant chemotherapy.

Treatment of germline BRCA-mutated, HER2-negative metastatic breast cancer.

Maintenance treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma after ≥16 weeks of first-line platinum-based chemotherapy without progression.

Treatment of metastatic castration-resistant prostate cancer (mCRPC) with HRR gene mutations after progression on enzalutamide or abiraterone.

Combination use with abiraterone and prednisone/prednisolone for BRCA-mutated mCRPC.

Therapeutic Target

Poly (ADP-ribose) polymerase (PARP), including PARP1, PARP2, and PARP3 enzymes. It is particularly effective in tumors with homologous recombination repair (HRR) deficiencies, such as those with BRCA1/2 mutations or genomic instability.

Active Ingredients

Olaparib

Dosage form

TABLET

specifications

150mg * 56 Tablets/Box

Description

Dosage and Administration

Recommended dose: 300 mg orally twice daily with or without food.

For moderate renal impairment (CLcr 31–50 mL/min): reduce to 200 mg twice daily.

Dose modifications required for concomitant use with strong or moderate CYP3A inhibitors.

Treatment duration varies by indication, ranging until disease progression, unacceptable toxicity, or up to 2 years (ovarian cancer) or 1 year (adjuvant breast cancer).

CATEGORY NAVIGATION